A study that analyzed different cell lines from the NCI60 database (using CellMiner), representing cancer types that typically receive treatment with erlotinib, such as breast cancer, colon cancer and NSCLC, identified TRIB3 at the top three genes that showed the strongest correlation with EGFR inhibition [96]. Here, TRIB3 is linked to malignant colon neoplasm.